- **Blockbuster Potential**: EMPAVELI on track for 50% penetration in 5,000 U.S. patients, with Q4 2025 achieving 5% market penetration.
- **SYFOVRE Resilience**: 17% YoY injection growth, 5-year data showing 1.5-year GA delay, and 2027 innovations (prefilled syringe, OCT-F).
- **Pipeline Breakthroughs**: APL-9099 (base editing) IND expected H2 2026; FSGS/DGF trials expand kidney disease reach.
- **Financial Strength**: $466M cash, $1B 2025 revenue, and disciplined spending to fund growth.

**【CEO Summary Section】**
- **2025 Progress**: Cedric highlighted Apellis' disciplined execution across three pillars: SYFOVRE in geographic atrophy (GA), EMPAVELI in rare kidney diseases, and pipeline innovation. SYFOVRE saw steady growth despite free goods usage, while EMPAVELI achieved 5% market penetration in its first full quarter post-launch. The pipeline includes APL-9099 (FcRn base editing) and APL-3007 (next-gen GA combo therapy).
- **SYFOVRE Updates**: Total injections grew 17% YoY, with 89,000 commercial doses in Q4. The prefilled syringe and OCT-F (AI-enabled functional OCT) are expected to drive 2027 growth. The 5-year GALE study showed SYFOVRE delays GA progression by 1.5 years.
- **EMPAVELI Momentum**: Launched in C3G and primary IC-MPGN, EMPAVELI achieved 5% penetration and 267 patient starts by year-end. It is the only therapy for ~2/3 of the U.S. patient population, with potential for 50% peak penetration.

**【CFO Financial Commentary】**
- **Revenue**: Full-year 2025 revenue was $1B, including a $275M one-time Sobi payment. SYFOVRE net revenue: $587M; EMPAVELI: $102M. Q4 SYFOVRE doses: 102,000 (89K commercial, 13K free goods).
- **Financial Health**: Cash of $466M; 2026 operating expenses expected to rise modestly due to new trials. Gross-to-net for SYFOVRE in Q4 was ~22%, expected to trend higher in 2026.
- **Milestones**: $25M milestone from Sobi for Aspaveli's EU approval; evaluating options to address $94M convertible debt.

**【Q&A Key Highlights】**
- **EMPAVELI Growth**: Cedric emphasized its potential to reach 50% of the 5,000 U.S. patient population, driven by pediatric and post-transplant segments. Q1 2026 start forms indicate steady pipeline growth.
- **SYFOVRE Access**: Co-pay programs reopened, but free goods usage remains variable. The prefilled syringe and OCT-F aim to improve workflow and patient engagement.
- **Pipeline Ambition**: APL-9099 (IND expected H2 2026) and FSGS/DGF trials position Apellis for long-term growth. GALLOP Phase II combo study with APL-3007 could extend GA efficacy.

Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript

- **FDA Approval Milestone**: EMPAVELI now treats 5,000+ rare kidney disease patients, with 152 patient starts in first 2 months.
- **Revenue Resilience**: $459M Q3 revenue (including $275M Sobi payment), SYFOVRE net $151M despite 4% injection growth headwinds.
- **Growth Drivers**: Prefilled syringe for SYFOVRE and FSGS/DGF trials set to launch, targeting $475M cash runway.
- **Key Risks**: Free goods usage ($40M headwind) and limited patient access programs constrain GA adoption.
- **Strategic Wins**: EMPAVELI's C3 targeting outperforms competitors, with 52% GA market share and 19/20 top nephrology accounts engaged.

**【CEO Summary Section】**
- Apellis achieved FDA approval for EMPAVELI in C3G and primary IC-MPGN, expanding its addressable market by ~5,000 patients.
- Q3 revenue was $459M, including $275M upfront payment from Sobi, with SYFOVRE net product revenue at $151M.
- EMPAVELI launch progress: 152 patient start forms received, with 50 from expanded access program transitioning to commercial drug.
- SYFOVRE maintains 52% new patient start share in GA, despite 4% injection growth driven by free goods usage.
- Long-term growth initiatives include prefilled syringe for SYFOVRE and expansion into FSGS and DGF kidney diseases.

**【CFO Financial Commentary】**
- Total revenue growth driven by Sobi royalty ($275M) and stable SYFOVRE demand.
- Operating expenses decreased 4% YoY to $235M, with disciplined cost management.
- Cash position of $475M supports operations, with discontinuation of factoring saving ~$5M annually.
- SYFOVRE gross-to-net adjustments remain stable, with modest degradation expected in Q4.

**【Q&A Highlights】**
- **EMPAVELI Launch Dynamics**: 19/20 top nephrology accounts submitted start forms, with 4-6 week time frame to initiate therapy.
- **SYFOVRE Challenges**: $40M headwind from free goods usage over 9 months; prefilled syringe expected to reinvigorate growth.
- **Pipeline Progress**: Phase II SYFOVRE/APL-3007 combo trial enrolling, targeting 3-month dosing; FSGS and DGF trials to begin by year-end.
- **Competitive Landscape**: EMPAVELI's differentiated efficacy (C3 targeting) vs. Fabhalta (C5 targeting) driving prescriber preference.
- **Access Issues**: Patient assistance programs constrained for SYFOVRE, impacting new starts despite strong demand.

Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript

- **EMPAVELI Breakthrough**: FDA approves for 5,000+ rare kidney patients, targeting $0.5B+ revenue potential. 
- **SYFOVRE Dominance**: 6% QoQ growth, 60% market share, $151M revenue despite $13M free goods impact. 
- **$275M Sobi Deal**: Validates Aspaveli's $1B+ potential, adds $645M liquidity. 
- **Pipeline Momentum**: Phase II combo study, pivotal trials for DGS/FSGS, 4-year SYFOVRE data shows increasing benefits.

**【CEO Summary Section】**
- FDA approves EMPAVELI for C3G and primary IC-MGN, expanding into rare nephrology with potential for 5,000+ patients. 
- SYFOVRE delivers $151M revenue, 6% QoQ injection growth, maintaining 60% market share in GA. 
- Capped royalty purchase agreement with Sobi secures $275M upfront, validating Aspaveli's blockbuster potential in rare kidney diseases.

**【CFO Financial Commentary】**
- Q2 total revenue: $178M (SYFOVRE: $151M, EMPAVELI: $21M, +5% QoQ). 
- Free goods impact: $13M in Q2, expected similar Q3-Q4. 
- Operating expenses: $212M (down 7% YoY), 2025 OpEx in line with 2024. 
- Cash position: $370M + $275M Sobi payment = $645M liquidity.

**【CFO on Aspaveli Royalty Agreement】**
- Sobi pays $275M upfront for 90% of ex-US royalties up to defined caps. 
- Milestones: $25M on EMA approval, long-term upside beyond caps. 
- No impact to existing Sobi milestones under 2020 agreement.

**【CMO and Pipeline Updates】**
- Phase II SYFOVRE/ATL-3007 combo study initiated for fewer injections, better efficacy. 
- Pivotal trials for DGS and FSGS (rare kidney diseases) to begin Q4. 
- 4-year SYFOVRE data shows increasing benefits over time, functional vision preservation.

**【Commercial Update】**
- SYFOVRE: 55% new patient starts, 60% market share, 97% compliance. 
- Free goods usage: 13,000 doses (40% growth), driven by copay funding shortages. 
- EMPAVELI launch: pediatric, post-transplant C3G, targeting 50+ EAP transitions by year-end.

**【Q&A Highlights】**
- Competitor claims 20%+ growth: Apellis maintains leadership via 4-year data, every-other-month dosing, 5 ASRS presentations vs 0 for competitor. 
- Free goods trends: $13M/Q2 impact expected to persist, 10-15% of injections in 2025. 
- SYFOVRE profitability: High-margin business with ~$150M annual revenue, >50% gross margin.

Apellis Pharmaceuticals (APLS)-31 Jul 25-2025 Q2 Earnings call transcript

- **SYFOVRE Growth Challenges**: 4% injection growth vs. 10% revenue decline due to inventory drawdown and sample usage
- **EMPAVELI Launch Momentum**: FDA Priority Review with PDUFA-28 for C3G/IC-MPGN
- **Financial Resilience**: $358M cash, flat OpEx, 20-25% gross-to-net margin guidance
- **Market Leadership**: >60% GA market share, 55% new patient starts
- **EMPAVELI Differentiation**: 68% proteinuria reduction vs. competitor's 34% in Phase 3

**【CEO Opening Remarks】**
- SYFOVRE injection demand grew 4% QoQ, but revenue fell due to channel inventory drawdown and increased sample usage (funding shortages in co-pay assistance programs). 
- SYFOVRE maintains >60% market share, with new patient starts at 55% by late April.
- EMPAVELI for C3G/IC-MPGN received FDA Priority Review with PDUFA date of July 28, 2025. Phase 3 VALIANT data shows 68% proteinuria reduction, eGFR stabilization, and C3c clearance.

**【CFO Financial Review】**
- SYFOVRE net product revenue: $130M (down 10% YoY)
- Key drivers:
  - $10M impact from co-pay assistance funding shortage
  - Q1 channel inventory drawdown
- Gross-to-net rate: ~20-25% for 2025
- Operating expenses remain flat YoY
- Cash balance: $358M (sufficient for ~2 years of operations)

**【Commercial Update】**
- 92,000 SYFOVRE doses delivered (82,000 commercial + 10,000 samples)
- DTC campaign drives 30% increase in website traffic vs. 2024
- EMPAVELI launch prep: 
  - 5,000+ U.S. patients in target C3G/IC-MPGN population
  - Field teams engaged with key accounts
  - Payer outreach for coverage

**【Key Q&A Takeaways】**
1. **Inventory Dynamics**: Q1 channel inventory returned to normal levels after Q4 build-up. No expectation of resolution for co-pay assistance funding shortage.
2. **Competitive Landscape**: SYFOVRE maintains >60% market share vs. competitor with limited label
3. **EMPAVELI Potential**: 52-week VALIANT data to be presented at ERA 2025
4. **Cash Position**: $358M cash + future product sales provide >2-year runway
5. **Tariff Mitigation**: Actively monitoring and planning for potential impacts

Apellis Pharmaceuticals (APLS)-7 May 25-2025 Q1 Earnings call transcript

- **Revenue Powerhouse**: SYFOVRE drives 120% YoY growth; full-year 2024 revenue doubles to $781M. 
- **EMPAVELI Breakthrough**: C3G/IC-MPGN Phase III data hits trifecta (proteinuria, C3 clearance, eGFR stability); H2 2025 launch on track. 
- **GA Market Dominance**: >60% share with 6 doses/year flexibility; only 10% of patients treated. 
- **Pipeline Momentum**: Phase II GA combo trial Q2 2025; FSGS/DGF trials H2 2025. 
- **Financial Strength**: $411M cash; stable OpEx for 2025. 


**【CEO Opening Remarks】**
- **2024 Milestones**: SYFOVRE achieved 120% YoY U.S. net revenue growth; Phase III data for EMPAVELI in C3G and ICF-PGN showed significant reductions in proteinuria and C3 deposits. 
- **Three Strategic Pillars**: 
  1. **GA Leadership**: SYFOVRE is the only GA product with a label allowing 6 doses/year and preferred payer status. 
  2. **EMPAVELI Expansion**: Targeting C3G, IC-MPGN, FSGS, and DGF with Phase III trials starting H2 2025. 
  3. **Pipeline Innovation**: Next-gen GA combo (SYFOVRE + APL-3007 siRNA) Phase II trial to begin Q2 2025. 
- **Market Position**: SYFOVRE maintains >60% market share; only 10% of diagnosed GA patients are treated. 

**【CFO Financial Overview】**
- **Q4 2024 Results**: Total revenue $213M (SYFOVRE: $168M, EMPAVELI: $23M). Full year 2024 revenue $781M (+98% YoY). 
- **Cost Management**: Gross to net ~20-25%; R&D/Sales & Admin expenses stable at $76M/$121M. 
- **Cash Position**: $411M cash; 2025 OpEx expected to remain flat. 

**【Q&A Key Takeaways】**
- **EMPAVELI Launch**: FDA validation for C3G/IC-MPGN expected H2 2025; 5,000+ U.S. patients targeted. 
- **SYFOVRE Dynamics**: Q1 2025 net revenue lower due to sample spike (5,000+ vials), but injection growth (+20% vs Q4) signals long-term demand. 
- **Pipeline Progress**: Phase II combo trial for GA; FSGS/DGF Phase III trials to start H2 2025. 
- **Competitive Edge**: SYFOVRE's flexible dosing and real-world data (40% GA growth reduction) differentiate from competitors. 

**【Commercial Strategy】**
- **DTC Campaign**: Phase 2 with Henry Winkler drives ~3,000 website visits post-SNL ad. 
- **Payer Strategy**: >50% new patient share in preferred formulary states; Aetna requires SYFOVRE first. 
- **International Expansion**: Australia approval; Switzerland review ongoing. 


Apellis Pharmaceuticals (APLS)-28 Feb 25-2024 Q4 Earnings call transcript

Apellis Pharmaceuticals (APLS)-5 Nov 24-2024 Q3 Earnings call transcript

Apellis Pharmaceuticals (APLS)-1 Aug 24-2024 Q2 Earnings call transcript

Apellis Pharmaceuticals (APLS)-7 May 24-2024 Q1 Earnings call transcript

Apellis Pharmaceuticals (APLS)-27 Feb 24-2023 Q4 Earnings call transcript

Apellis Pharmaceuticals (APLS)-1 Nov 23-2023 Q3 Earnings call transcript

- **Strong Q2 Sales Despite Safety Concerns**: $67M SYFOVRE revenue, 68,000 vials distributed.
- **Efficacy Data Standout**: 45% GA lesion growth reduction in GALE study.
- **Rare Vasculitis Events**: 7 confirmed cases, sporadic occurrence, no clinical trial correlation.
- **Financial Resilience**: $616M cash runway; cautious sales outlook.
- **Global Expansion**: EU approvals pending for early 2024 launch.

**【Management Opening Remarks】**
- Reported $90 million in total product sales for Q2 2023, including $67 million for SYFOVRE.
- Over 68,000 vials of SYFOVRE distributed to physicians, impacting tens of thousands of patients.
- Highlighted rare safety events of vasculitis (7 confirmed cases) and ongoing investigation.

**【CEO Commentary】**
- SYFOVRE demonstrated strong efficacy in GALE study: 45% reduction in nonsubfoveal GA lesion growth over 24-30 months.
- Vasculitis events occurred sporadically, with no correlation to clinical trial data.
- 60,000+ injections administered in real-world use, with events not increasing over time.
- Two patients fully recovered vision, while others remain under close monitoring.

**【CFO Financial Commentary】**
- $616 million in cash as of Q2, providing runway into Q1 2025.
- Sales trajectory may face near-term challenges due to safety concerns.
- Disciplined spending and transparent updates on financial strategy.

**【Q&A Highlights】**
- **Inventory & Distribution**: 68,000 vials distributed, ~60,000 administered; physicians hold ~1 week of inventory.
- **Manufacturing & Safety**: No manufacturing issues identified; SYFOVRE formulation same as clinical trials.
- **Physician Behavior**: 1/3 of surveyed physicians plan to continue prescribing; 1/3 may pause in new patients.
- **Regulatory Updates**: Safety events reported to global regulators; EU approvals expected Q1 2024.
- **Commercial Kit**: Prefilled syringe development ongoing but years away; ancillary devices under investigation.
- **Patient Outcomes**: Two full recoveries, two severe impairments, three evolving cases.


Actual									-2.29	-1.79	0.93	-2.32	-2.72	-2.28	-1.61	-1.42	-1.46	-1.75	-1.5	-1.56	-1.02	-1.17	-0.73	-0.54	-0.3	-0.46	-0.29	-0.74	-0.33	1.67	0.47
Forecast									-1.3753	-1.5683	-0.6665	-1.6366	-1.7165	-1.6936	-1.5381	-1.3337	-1.4144	-1.4634	-1.5205	-1.4781	-1.3597	-0.9935	-0.7307	-0.4775	-0.3062	-0.2949	-0.3695	-0.3444	-0.4655	1.5787	-0.3783
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-66.51%	-14.14%	+239.53%	-41.76%	-58.46%	-34.62%	-4.67%	-6.47%	-3.22%	-19.58%	+1.35%	-5.54%	+24.98%	-17.77%	+0.10%	-13.09%	+2.02%	-55.99%	+21.52%	-114.87%	+29.11%	+5.78%	+224.24%

APLS(Delisted)

APLS(Delisted)

Apellis (APLS) Earnings

APLS Q4 2025 Earnings

EPS

Revenue

Earnings Call

You can ask Aime